The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Phase Ib study of venetoclax plus azacitidine in patients with R/R MDS
Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, describes the results of a Phase Ib study evaluating the combination of azacitidine and venetoclax in patients with relapsed/refractory (R/R) myelodysplastic syndromes (MDS) (NCT02966782). The study included 46 heavily pre-treated patients with higher-risk MDS. Treatment with venetoclax plus azacitidine resulted in a range of adverse effects including infection and led to treatment discontinuation in 20% of patients. The overall response rate (ORR) was 38.6% and median overall survival (OS) was 12.6 months. This combination should be further evaluated in a larger randomized study. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
